New eczema pill shows promise in early safety trial
NCT ID NCT07336940
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new oral drug called ENV-294 in 9 adults with moderate-to-severe atopic dermatitis (eczema). Participants took the drug once daily for 28 days and had weekly checkups. The main goal was to see if the drug is safe and tolerable, while also looking for any changes in eczema severity.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ENV-294
- What this could lead to
- If it works, this could point toward a new daily pill to ease symptoms of moderate-to-severe atopic dermatitis.
- What could go wrong
- This is a very early, small Phase 1 trial with only 9 participants. It primarily checks safety, not effectiveness. The drug may not improve symptoms or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
9 people
The number who actually took part.
- Started
-
Sep 2025
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Be male or female participants who are 18 to 75 years of age * Have chronic AD (also known as atopic eczema) that was diagnosed at least 12 months prior to the first study visit * Have a history of inadequate response or intolerance to topical corticosteroids or other topical treatments for used atopic dermatitis * Have moderate-to-severe atopic dermatitis, at the first two study visits * Use an emollient (except those containing urea) daily for at least 1 week prior to the first study visit and throughout the study Exclusion Criteria: * Have any uncontrolled current or recurrent concomitant illness (eg, hepatitis B surface antigen, hepatitis C virus, or other condition) that could affect the study drug, clinical or laboratory assessments, or could impact participant safety. * Are using any medication (prescription or over-the-counter) that may interfere with the study product safety evaluations within 14-days prior to the second study visit. * Have the presence of any concomitant skin conditions (eg, psoriasis, seborrheic dermatitis) or have large tattoos that would interfere with clinical assessment, evaluation of AD, or treatment response.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Dermatology Clinical Research, Inc.
Fremont, California, 94538, United States
-
J & S Studies
College Station, Texas, 77845, United States
-
Skin Sciences, PLLC
Louisville, Kentucky, 40217, United States
-
Texas Dermatology and Laser Specialists
San Antonio, Texas, 78218, United States
-
Virginia Dermatology & Skin Cancer Center
Norfolk, Virginia, 23502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.